Galectin-3 Emerges as New Alzheimer's Target
Researchers at Lund University report that the protein galectin-3 shapes how amyloid builds up in the brain, prompting a planned Phase II trial of a blocking antibody.
Updated on Nov. 20, 2026 in Alzheimer’s

Lund University researchers identified galectin-3 as a potential new therapeutic target for Alzheimer's disease. US regulators have authorized a Phase II clinical trial of an antibody designed to block galectin-3.
Why it matters
Galectin-3 could offer a complementary target to existing Alzheimer's treatments, expanding the approaches researchers can pursue against the disease. Findings from the planned trial will show whether inhibiting galectin-3 is a viable treatment strategy.
The evidence combines mouse-model experiments with analysis of brain tissue from nine human donors. The sample size is small, and whether the mouse results translate to people has not been established.
The players
Lund University
A public research university in Lund, Sweden, and one of the oldest universities in Scandinavia, which led the study identifying galectin-3's role in Alzheimer's.
The details
Galectin-3 binds to beta-amyloid and to amyloid fibrils, altering their structure as they grow. Inside microglia, it sits in lysosomes, where it influences how amyloid is processed. In mouse models, removing galectin-3 reduced plaque size and nerve-ending damage and shifted microglia toward a TREM2-rich state.
Timeline
Study findings were published on November 20, 2026.
Health Landscape
Most Alzheimer's drug development has centered on amyloid, and galectin-3 offers a complementary target that acts on how amyloid forms and is processed. Whether this shift broadens treatment options will depend on results from the planned Phase II trial.
For now, galectin-3 blockade remains investigational and is not available as a treatment. Readers managing Alzheimer's risk should continue to follow established care guidance while the Phase II trial results are awaited.
The takeaway
Alzheimer's research is widening beyond amyloid plaques to the biology that shapes them, and galectin-3 is one such candidate. The next confirmation will come from human trial data rather than laboratory models.
What happens next
The Phase II clinical trial of the galectin-3 blocking antibody has been authorized by US regulators, with results expected to show whether galectin-3 inhibition is a viable treatment.
Further reading
Explore more on Alzheimer’s research and treatment developments.



